BR112013020283A2 - "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos" - Google Patents
"uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"Info
- Publication number
- BR112013020283A2 BR112013020283A2 BR112013020283A BR112013020283A BR112013020283A2 BR 112013020283 A2 BR112013020283 A2 BR 112013020283A2 BR 112013020283 A BR112013020283 A BR 112013020283A BR 112013020283 A BR112013020283 A BR 112013020283A BR 112013020283 A2 BR112013020283 A2 BR 112013020283A2
- Authority
- BR
- Brazil
- Prior art keywords
- cognitive impairment
- cognitive
- sv2a
- valproate
- treatment
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 5
- 208000028698 Cognitive impairment Diseases 0.000 title abstract 4
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 title abstract 2
- 229940102566 valproate Drugs 0.000 title abstract 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title 1
- 229960004002 levetiracetam Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 title 1
- 229950000852 seletracetam Drugs 0.000 title 1
- 210000002504 synaptic vesicle Anatomy 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 abstract 1
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
métodos e composições para melhora da função cognitiva a presente invenção refere-se a métodos e a composições para tratamento de distúrbios do sistema nervoso central (snc) com deficiência congnitiva. em particular, ela refere-se ao uso de inibidores de glicoproteína de vesícula sináptica 2a (sv2a), sozinhos ou em combinação com valproato, em tratamento de distúrbios do sistema nervoso central (snc) com deficiência cognitiva em um indivíduo com necessidade ou sob risco do mesmo incluindo, sem limitação, os indivíduos tendo ou sob risco de deficiência cognitiva relacionado com a idade, deficiência cognitiva leve (mci), mci amnéstica (amci), deficiência de memória relacionada com a idade (aami), declínio cognitivo relacionado com a idade (arcd), demência, doença de alzheimer (ad), ad prodrômica, distúrbio do estresse pós-traumático (ptsd), esquizofrenia, esclerose lateral amiotráfica e deficiência cognitiva relacionada com terapia para câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441251P | 2011-02-09 | 2011-02-09 | |
| PCT/US2012/024556 WO2012109491A1 (en) | 2011-02-09 | 2012-02-09 | Methods and compositions for improving cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013020283A2 true BR112013020283A2 (pt) | 2016-07-19 |
Family
ID=46638963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013020283A BR112013020283A2 (pt) | 2011-02-09 | 2012-02-09 | "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos" |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120214859A1 (pt) |
| EP (2) | EP2672822A4 (pt) |
| JP (6) | JP2014505108A (pt) |
| CN (2) | CN103476255A (pt) |
| AU (6) | AU2012214303A1 (pt) |
| BR (1) | BR112013020283A2 (pt) |
| CA (1) | CA2826765C (pt) |
| RU (1) | RU2665021C2 (pt) |
| WO (1) | WO2012109491A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018208662B2 (en) * | 2012-11-14 | 2020-07-23 | The Johns Hopkins University | Methods and Compositions for Treating Schizophrenia |
| WO2014078568A1 (en) * | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968237A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| WO2014144546A1 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositons for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| DK3096790T3 (da) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
| US10925834B2 (en) | 2015-05-22 | 2021-02-23 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CN112569216B (zh) * | 2019-09-30 | 2022-02-15 | 厦门大学 | 戊酸衍生物在治疗唐氏综合征中的应用 |
| WO2023183623A1 (en) | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| WO2024039886A1 (en) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN115517682B (zh) * | 2022-11-25 | 2023-01-31 | 四川大学华西医院 | 基于胃肠电信号的认知功能障碍预测系统及构建方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US7090985B2 (en) * | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| EP1625378A4 (en) * | 2002-12-03 | 2007-05-16 | Ucb Sa | METHOD OF IDENTIFYING AGENTS FOR THE TREATMENT OF CEREALS, NEUROLOGICAL DISEASES, ENDOCRINOPATHIES AND HORMONE DISEASES |
| CN101027047A (zh) * | 2002-12-03 | 2007-08-29 | Ucb公司 | 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法 |
| US9125939B2 (en) * | 2003-05-23 | 2015-09-08 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| EP1874282B1 (en) * | 2005-04-06 | 2010-09-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of cns disorders |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| KR20080030546A (ko) * | 2005-07-26 | 2008-04-04 | 유씨비 파마, 에스.에이. | 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법 |
| EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| WO2007141002A1 (en) * | 2006-06-08 | 2007-12-13 | Ucb Pharma, S.A. | Co-crystals of pyrrolidinones |
| WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| US20090176740A1 (en) * | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| CN102170874A (zh) * | 2008-08-06 | 2011-08-31 | 高思福斯中心（控股）有限公司 | 治疗精神病学障碍的组合物和方法 |
| EP3260118B1 (en) * | 2008-10-16 | 2021-03-24 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| CN101647789B (zh) * | 2009-09-01 | 2011-08-17 | 天津药物研究院药业有限责任公司 | 左乙拉西坦缓释微丸胶囊制剂 |
| EP2533645B1 (en) * | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
-
2012
- 2012-02-09 WO PCT/US2012/024556 patent/WO2012109491A1/en active Application Filing
- 2012-02-09 CN CN201280014797XA patent/CN103476255A/zh active Pending
- 2012-02-09 BR BR112013020283A patent/BR112013020283A2/pt not_active Application Discontinuation
- 2012-02-09 JP JP2013553575A patent/JP2014505108A/ja not_active Withdrawn
- 2012-02-09 EP EP12744250.7A patent/EP2672822A4/en not_active Withdrawn
- 2012-02-09 AU AU2012214303A patent/AU2012214303A1/en not_active Abandoned
- 2012-02-09 RU RU2013141155A patent/RU2665021C2/ru active
- 2012-02-09 CA CA2826765A patent/CA2826765C/en active Active
- 2012-02-09 CN CN201811403097.5A patent/CN109662961A/zh active Pending
- 2012-02-09 EP EP18161109.6A patent/EP3400934A1/en active Pending
- 2012-02-09 US US13/370,253 patent/US20120214859A1/en not_active Abandoned
-
2016
- 2016-04-27 AU AU2016202670A patent/AU2016202670A1/en not_active Abandoned
- 2016-07-04 JP JP2016132218A patent/JP2016172772A/ja not_active Withdrawn
-
2018
- 2018-02-22 AU AU2018201303A patent/AU2018201303A1/en not_active Abandoned
- 2018-03-27 JP JP2018060195A patent/JP2018100305A/ja not_active Withdrawn
-
2019
- 2019-11-19 AU AU2019268069A patent/AU2019268069A1/en not_active Ceased
-
2020
- 2020-02-28 JP JP2020033698A patent/JP2020079318A/ja active Pending
-
2021
- 2021-01-19 AU AU2021200325A patent/AU2021200325B2/en active Active
- 2021-08-12 JP JP2021131734A patent/JP2021175759A/ja active Pending
-
2022
- 2022-03-14 US US17/693,901 patent/US20230033195A1/en active Pending
- 2022-08-25 AU AU2022221492A patent/AU2022221492A1/en not_active Abandoned
-
2023
- 2023-07-21 JP JP2023119159A patent/JP2023126654A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013141155A (ru) | 2015-03-20 |
| JP2018100305A (ja) | 2018-06-28 |
| CN109662961A (zh) | 2019-04-23 |
| WO2012109491A1 (en) | 2012-08-16 |
| JP2021175759A (ja) | 2021-11-04 |
| JP2016172772A (ja) | 2016-09-29 |
| JP2023126654A (ja) | 2023-09-07 |
| RU2018129580A3 (pt) | 2022-03-25 |
| AU2012214303A1 (en) | 2013-09-12 |
| EP2672822A4 (en) | 2014-08-27 |
| AU2018201303A1 (en) | 2018-03-15 |
| AU2019268069A1 (en) | 2019-12-12 |
| US20230033195A1 (en) | 2023-02-02 |
| RU2665021C2 (ru) | 2018-08-24 |
| AU2016202670A1 (en) | 2016-05-19 |
| JP2020079318A (ja) | 2020-05-28 |
| JP2014505108A (ja) | 2014-02-27 |
| CN103476255A (zh) | 2013-12-25 |
| EP2672822A1 (en) | 2013-12-18 |
| CA2826765C (en) | 2021-04-06 |
| RU2018129580A (ru) | 2019-03-20 |
| AU2022221492A1 (en) | 2022-09-22 |
| US20120214859A1 (en) | 2012-08-23 |
| AU2021200325B2 (en) | 2022-07-28 |
| AU2021200325A1 (en) | 2021-03-18 |
| EP3400934A1 (en) | 2018-11-14 |
| CA2826765A1 (en) | 2012-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013020283A2 (pt) | "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos" | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| MX2019010577A (es) | Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo. | |
| MX2011010353A (es) | Composicion farmaceutica. | |
| BR112014004465A2 (pt) | compostos e composições como inibidores de pdgfr cinase | |
| BR112013033417A2 (pt) | compostos terapêuticos e métodos relacionados de uso | |
| EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
| EA201170571A1 (ru) | Способы и композиции для улучшения когнитивной функции | |
| BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
| MX2008012479A (es) | Tratamiento de enfermedades neurodegenerativas. | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| BR112012019923A2 (pt) | métodos e composições para melhorar a função cognitiva | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| DE602007007618D1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
| MX2017015752A (es) | Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo. | |
| BR112012009121A2 (pt) | Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central | |
| BRPI0520258A2 (pt) | uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina | |
| BR112014024308A8 (pt) | uso de neuregulina para tratar lesão de nervo periférico | |
| BR112017004729A2 (pt) | processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea | |
| BR112018014762A2 (pt) | método de tratamento da doença de alzheimer (da) precoce | |
| EA201500294A1 (ru) | Ноотропные композиции для улучшения свойств памяти | |
| MA41985B1 (fr) | Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux | |
| PH12018502703A1 (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/36 Ipc: A61K 31/20 (2006.01), A61K 31/4015 (2006.01), A61K |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |